EGFR and neoplasm: We identified key epithelial–immune interactions in high EGFR expressing tumours such as LGALS3–LAG3, PLAU–PLAUR, MDK–(ITGA4+ITGB1) which can be therapeutically targeted with available inhibitors such as relatlimumab,7 upamostat8 and natalizumab9 alongside currently prescribed anti‐EGFR cetuximab10 to increase immune infiltration within tumour for potential prognostic benefit.